Clinical trials: Ovarian Diseases
Ovarian Cancer, Peritoneal Cancer
Abraxane/Bevacizumab
The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Trial name
- NCT01821859
- Testing
- Abraxane, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Polycystic Ovary Syndrome
Dose Adjusted vs. Fixed Dose Unilateral Laparoscopic Ovarian Drilling in PCOS Patients
Polycystic ovary syndrome (PCOS) is a common endocrine disorder and a leading cause of infertility in women of reproductive age affecting up to 20% of them.
- Trial name
- NCT04021940
- Testing
- ULOD
- Volunteers
- 128 people
- Sponsor
- Hatem AbuHashim
Ovarian Cancer (OvCa), Ovarian Cancer Metastatic
O-RADS MRI System on Early Detection of Ovarian Cancer
This study is designed to prospectively enroll individuals with suspected or potential risk of ovarian cancer across multiple centers.
- Trial name
- NCT07009743
- Testing
- MRI contrast-enhancing agents
- Where
- China
- Volunteers
- 2,549 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Solid Tumors, Ovarian Cancer
A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other…
- Conditions
- Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT06873555
- Testing
- DC05F01
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Heronova Pharmaceuticals
Ovarian Cancer
Oxford Ovarian Cancer Predict Chemotherapy Response 01
The purpose of the study is to understand why there are differences between individuals in the way they respond to paclitaxel chemotherapy.
- Trial name
- OXO-PCR-01 (NCT01770535)
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University of Oxford
Ovarian Neoplasms, Pancreatic Neoplasms
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
The purpose of this study is to determine the recommended dose of siltuximab monotherapy, in participants with solid malignant (cancerous) tumors (a mass in a specific area) and to estimate the clinical benefit of siltuximab…
- Conditions
- Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT00841191
- Testing
- CNTO 328; Anti-interleukin-6 monoclonal antibody
- Where
- 12 sites in United States, Belgium and 3 more
- Volunteers
- 84 people
- Sponsor
- Centocor, Inc.
Ovarian Cancer, Epithelial Ovarian Cancer
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
The purpose of this study is to see whether participants who are assigned to a multimodal prehabilitation intervention during chemotherapy are able to adhere with exercise and nutrition program to prepare for their cancer surgery.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT06412510
- Testing
- Prehabilitation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Ovarian Cancer, Ovarian Neoplasms
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
This is a phase II/III randomized controlled trial to evaluate efficacy of platinum-based chemotherapy vs conventionally prescribed non-platinum monochemotherapy in patients with platinum-resistant ovarian cancer
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Serous Adenocarcinoma, BRCA1 Mutation
- Trial name
- EPITOC (NCT04055038)
- Testing
- Platinum-Based Drug, Conventional chemotherapy
- Where
- Russia
- Volunteers
- 164 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Complex Ovarian Cyst
Diagnostic Accuracy of Ultrasound and Tumors Markers in Diagnosis of Complex Ovarian Cysts
Cystic ovarian lesions are more common in adolescences due to onset of hormonal activity in prepubertal age. Most cysts are functional but a malignant etiology must nevertheless always be eliminated.
- Trial name
- NCT07005089
- Testing
- Laparotomy or laparoscopic ovarian cystectomy
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Al-Azhar University
Ovarian Cancer, Ovarian Neoplasms
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT05261490
- Testing
- maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Obese, Infertility
Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients
The purpose of this study is to compare two fertility protocols in obese women with Polycystic Ovarian Syndrome who are candidates for In Vitro Fertilization (IVF).
- Conditions
- Obese, Infertility, Polycystic Ovary Syndrome
- Trial name
- NCT01473459
- Testing
- IVM (In Vitro Maturation) Treatment, IVF (In Vitro Fertilization) Antagonist Protocol
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hillel Yaffe Medical Center
Solid Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
- Trial name
- NCT06161025
- Testing
- R-DXd, Paclitaxel, Topotecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 860 people
- Sponsor
- Daiichi Sankyo
Premature Ovarian Failure
Evolution of Sexual Life Quality of Women With POI Before and After Introduction of Hormone Replacement Therapy
The aim of this study is to evaluate the evolution of quality of sex life of women with POI after introduction hormone replacement therapy through the FSFI scale
- Trial name
- SEX-POInt (NCT05890417)
- Testing
- questionnaire
- Where
- 2 sites in France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Bordeaux
Breast Cancer, Breast Cancer Metastatic
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers.
- Conditions
- Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Trial name
- INX-315-01 (NCT05735080)
- Testing
- INX-315, Fulvestrant, Abemaciclib
- Where
- 18 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Incyclix Bio
Ovarian Cancer
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer.
- Trial name
- NCT03639246
- Testing
- AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD)
- Where
- 16 sites in United States
- Volunteers
- 53 people
- Sponsor
- Aravive, Inc.
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Polycystic Ovary Syndrome
Reproductive Endocrinology Oxford Study (RepOx)
This is a prospective observational study that aims to identify the underlying mechanisms of PolyCystic Ovarian Syndrome (PCOS) and associated comorbidities such as subfertility, miscarriage; and pregnancy complications such as…
- Trial name
- RepOx (NCT05177562)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 1,175 people
- Sponsor
- University of Oxford
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Epithelial Ovarian Cancer
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
Estrogens are implicated in the development of ovarian cancer and estrogen receptors (ER) alpha and beta are present in 20-100% of ovarian cancer patients.
- Trial name
- NCT01439490
- Testing
- FES-PET
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.